CIRCA Scientific Expands Access with CrossWise™ RF Transseptal Access System
CIRCA Scientific is making significant strides in the electrophysiology field, recently announcing the successful completion of the Limited Market Release (LMR) of its innovative
CrossWise™ RF Transseptal Access System. This cutting-edge technology is now commercially available across the United States and supports a broader range of heart procedures, a leap forward following its FDA clearance in September 2024.
Key to the CrossWise system is its unique
zero-exchange RF technology that utilizes a specialized cannula designed to enhance procedure efficiency and precision during septal crossings. This approach minimizes the number of procedural steps and aims to reduce potential complications associated with traditional methods. The flexibility offered by the CrossWise cannula allows for precise and stable positioning, even in complex cardiac anatomies.
An exciting development for medical professionals, the system’s enhanced compatibility now encompasses various sheath options, including the FARADRIVE and VIZIGO sheaths. This expanded compatibility positions CrossWise as a versatile tool suitable for nearly all left atrial access procedures, meeting the diverse needs of electrophysiologists.
Significant Performance Validation
The efficacy and reliability of CrossWise have been substantiated through recent bench-top validations presented at the Heart Rhythm Society (HRS) Annual Scientific Sessions. Doctors Michael Lloyd and Rand Ibrahim from Emory University provided compelling evidence of the system's performance. Their studies revealed that the CrossWise system effectively creates controlled punctures in challenging septal conditions, including tissue that is thickened or fibrotic. Remarkably, successful crossings were achieved in as little as 290 milliseconds.
The design eliminates the necessity for wire or sheath exchanges, which can complicate and prolong procedures. By focusing on delivering energy through a specially designed cannula, CrossWise enhances both procedural efficiency and efficacy. This innovative engineering not only contributes to better outcomes but also instills confidence in healthcare providers tasked with performing intricate cardiac interventions.
Commitment to Innovative Access Technologies
Lee Geist, CEO of CIRCA Scientific, expressed enthusiasm about the progression of the CrossWise system, stating, "The completion of our Limited Market Release validates the performance and procedural versatility of the CrossWise system. Physicians' feedback has been overwhelmingly positive, particularly regarding the sense of control and precision it brings to the septal crossing process." With the newly expanded compatibility, the CrossWise system is now equipped to support virtually all procedures requiring access to the left side of the heart.
In the coming months, CIRCA Scientific is poised to continue its rollout of the CrossWise system, ensuring it reaches a wider network of healthcare providers dedicated to improving patient outcomes in the field of electrophysiology. The company maintains a strong focus on creating innovative access technologies designed to enhance the capabilities of medical professionals, ultimately advancing patient care.
About CIRCA Scientific
CIRCA Scientific is committed to developing pioneering technologies that foster improved access and control for intricate medical procedures. Guided by a
CardioCentric™ approach, the company aims to enhance procedural success rates while empowering physicians with reliable solutions. More details about CIRCA Scientific's range of cardiac solutions can be found at their official website:
www.circascientific.com.
As CIRCA Scientific continues its journey towards revolutionizing access in electrophysiology, the healthcare community can look forward to the advancements that the CrossWise system promises to deliver.